Author/Authors :
Nikeghalian, S. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Davari, H. R. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Kakaei, F. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Shamsaeefar, A. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Sanei, B. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Geramizadeh, B. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Moini, M. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Sahmeddini, M. A. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران , Malek-Hosseini, S. A. shiraz university of medical sciences - Nemazi Hospital, Organ Transplant Research Center, ايران
Abstract :
Multivisceral transplantation (MVTx) is the term used to describe concurrent transplantation of the stomach, pancreaticoduodenal complex, small intestine, and liver. Modified MVTx (MMVTx), the liver is not transplanted [1]. This technique was first described by Starzl, et al, [2] in dogs in 1960. The first patient who underwent this procedure was a 6-year-old girl with liver failure due to short bowl syndrome in 1983 [3]. With introduction of cyclosporine, survival beyond the immediate post-operative period became possible [3] so that the first patient who discharged from hospital after this procedure was reported in December 1989 [4]. In spite of development of new immunosuppressive protocols (especially the use of induction therapy with monoclonal antibodies and use of tacrolimus for preventing intestinal rejection), new surgical techniques, novel diagnostic instruments for graft monitoring, and better candidate selection, this procedure is rarely performed in the world [1,5,6]. Herein, we report on our first experience with MMVTx in a 30-year-old man with advanced desmoid tumor in Shiraz Transplant Center, Namazi Hospital, Shiraz, southern Iran.
